Načítá se...
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
Programmed death-1 (PD-1) and its ligand are part of the immune checkpoint pathway that down-regulates effector T cells in immune response, thereby causing immune suppression. The PD-1/programmed death-ligand 1 (PD-L1) pathway can be blocked by antibodies to reverse tumor-mediated immunosuppression....
Uloženo v:
| Vydáno v: | J Gynecol Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5540723/ https://ncbi.nlm.nih.gov/pubmed/28657225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2017.28.e64 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|